Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:CRBUNASDAQ:DTILNASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.47+5.0%$1.48$1.10▼$2.43$77.82M2.92143,504 shs77,868 shsCRBUCaribou Biosciences$1.34+4.7%$0.97$0.66▼$3.00$119.05M2.441.34 million shs2.07 million shsDTILPrecision BioSciences$4.79+1.9%$5.06$3.61▼$11.09$52.12M1.48187,996 shs240,913 shsSGMOSangamo Therapeutics$0.46-6.8%$0.59$0.30▼$3.18$114.51M1.198.91 million shs4.71 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+6.52%+10.53%-3.29%+13.08%-27.05%CRBUCaribou Biosciences+4.69%+20.72%+32.02%+28.85%-18.29%DTILPrecision BioSciences+1.91%-2.24%+3.01%-12.11%-52.57%SGMOSangamo Therapeutics-6.84%-6.82%-8.50%-47.21%+8.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis3.372 of 5 stars3.55.00.00.02.32.50.6CRBUCaribou Biosciences2.5227 of 5 stars3.53.00.00.01.81.70.6DTILPrecision BioSciences4.1348 of 5 stars3.53.00.04.60.61.71.3SGMOSangamo Therapeutics1.3384 of 5 stars3.32.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$4.00172.11% UpsideCRBUCaribou Biosciences 3.00Buy$8.50534.33% UpsideDTILPrecision BioSciences 3.00Buy$47.00881.21% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$4.50883.61% UpsideCurrent Analyst Ratings BreakdownLatest CRBU, CLLS, DTIL, and SGMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/14/2025SGMOSangamo TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.004/7/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$49.22M1.66N/AN/A$2.36 per share0.62CRBUCaribou Biosciences$9.99M12.47N/AN/A$2.79 per share0.48DTILPrecision BioSciences$68.70M0.77N/AN/A$6.87 per share0.70SGMOSangamo Therapeutics$57.80M1.85N/AN/A$0.11 per share4.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)CRBUCaribou Biosciences-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)SGMOSangamo Therapeutics-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)Latest CRBU, CLLS, DTIL, and SGMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/12/2025Q1 2025SGMOSangamo Therapeutics-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million3/26/2025Q4 2024DTILPrecision BioSciences-$2.09-$3.20-$1.11-$2.22$4.28 million$3.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.441.671.67CRBUCaribou BiosciencesN/A7.637.63DTILPrecision BioSciences0.456.626.62SGMOSangamo TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%CRBUCaribou Biosciences77.51%DTILPrecision BioSciences37.99%SGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%CRBUCaribou Biosciences8.28%DTILPrecision BioSciences4.50%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableCRBUCaribou Biosciences10093.00 million85.30 millionOptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataSGMOSangamo Therapeutics480233.17 million223.61 millionOptionableCRBU, CLLS, DTIL, and SGMO HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Acquires 698,296 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)June 6, 2025 | marketbeat.comTwo Sigma Advisers LP Buys Shares of 707,555 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)June 3, 2025 | marketbeat.comH.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)May 31, 2025 | insidermonkey.comSangamo Therapeutics (NASDAQ:SGMO) Lowered to "Sell" Rating by Wall Street ZenMay 31, 2025 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of "Moderate Buy" by AnalystsMay 31, 2025 | marketbeat.comStockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO)May 24, 2025 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Now Covered by StockNews.comMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Takes $2.32 Million Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)May 23, 2025 | marketbeat.comSangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayMay 12, 2025 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 12, 2025 | businesswire.comSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingMay 12, 2025 | businesswire.comSangamo Therapeutics Q1 2025 Earnings PreviewMay 12, 2025 | msn.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%May 10, 2025 | aaii.comSangamo Therapeutics Sets Sights on 2026 BLA Filing for Fabry Disease Gene TherapyMay 7, 2025 | precisionmedicineonline.comSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseMay 7, 2025 | finance.yahoo.comSangamo Therapeutics Announces First Quarter 2025 Earnings CallMay 6, 2025 | businesswire.comSangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 1, 2025 | zacks.comSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)April 28, 2025 | businesswire.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 10.12%April 21, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBU, CLLS, DTIL, and SGMO Company DescriptionsCellectis NASDAQ:CLLS$1.47 +0.07 (+5.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.70%) As of 06/20/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Caribou Biosciences NASDAQ:CRBU$1.34 +0.06 (+4.69%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.38 +0.04 (+2.99%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Precision BioSciences NASDAQ:DTIL$4.79 +0.09 (+1.91%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.75 -0.04 (-0.84%) As of 06/20/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Sangamo Therapeutics NASDAQ:SGMO$0.46 -0.03 (-6.84%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.47 +0.01 (+2.95%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
